Richard C. Jordan, DDS, PhD, FRCPath.jpg
(415) 608-9378

Selected Awards & Honors

Fellow, American College of Dentists. 2011.

Mentor of the Year Award, UCSF School of Dentistry. 2007.

Fellow, Royal College of Pathologists (FRCPath). 2007.

Distinguished Teaching Award, UCSF School of Dentistry. 2005.

Richard C. Jordan, DDS, PhD, FRCPath

Professor of Oral Pathology, Pathology and Radiation Oncology

I feel fortunate to have joined this group of outstanding dermatopathologists. I believe that my training, experience and expertise in oral and maxillofacial pathology expands the scope and breadth of services that we are able to offer the medical and dental community for their diagnostic pathology needs.

I initially trained as a dentist at the University of Toronto that was followed by an internship at the Toronto Western Hospital (now the University Health Network). Following training in anatomic pathology I completed a residency in oral and maxillofacial pathology under the direction of Dr. Jim Main. I also completed a fellowship in oral medicine and then a Master of Science degree in oral pathology. I was fortunate to be able to train with Professor Paul Speight at the University of London were I was awarded a PhD degree in Experimental Pathology. My first faculty position was at the University of Toronto where I practiced oral pathology and oral medicine and developed a research program in oral cancer.

In 2000 I relocated to the University of California San Francisco and have been director of the oral pathology service since 2004. I have published over 130 peer reviewed publications, many invited reviews and I am the author of two leading textbooks, one in oral pathology
(Regezi, Sciubba and Jordan. Oral Pathology: Clinical pathologic correlations 6th ed) and the other in oral medicine (Lewis and Jordan. Color Handbook of Oral Medicine 2nd edition).

I am also the Medical Director (working with Dr. Nilsa Ramirez and Dr. Soon Paik) of the NRG Oncology Biospecimen Bank that is based in San Francisco, Columbus OH and Pittsburgh PA supporting phase II and phase III practice changing therapeutic trials for head and neck, breast, colorectal, lung, prostate and brain cancers. Enrolling 5099 patients each year, this biospecimen bank collects, stores, reviews and distributes over 150,000 biospecimens each year as part of the primary trials and translational research.

I am delighted to contribute to the UCSF Dermatopathology and Oral Pathology Service
and enjoy providing a high level of diagnostic pathology and expert opinion for clinicians and pathologists for lesions in the head and neck. 


Back to list of faculty →

Speaking Events

Selected Publications

Antonescu CR, Katabi N, Zhang L, Sung YS, Seethala RR, Jordan RC, Perez-Ordoñez B, Have C, Asa SL, Leong IT, Bradley G, Klieb H, Weinreb I. EWSR1-ATF1 fusion is a novel and consistent finding in hyalinizing clear-cell carcinoma of salivary gland. Genes Chromosomes Cancer. 2011 Jul;50(7):559-70.

Chung CH, Zhang Q, Hammond EM, Trotti AM, Wang H, Spencer S, Zhang H-Z, Cooper J, Jordan RC, Rotman MH, Ang KK. Integrating EGFR Assay with Clinical Parameters Improves Risk Classification for Relapse and Survival in Head and Neck Squamous Cell Carcinoma. International journal of radiation oncology, biology, physics 2011 Oct 1;81(2):331-8.

Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, Jiang B,  Goodman MT, Sibug-Saber M, Cozen W, Lui L,  Lynch CF, Wentzensen N, Jordan RC, Altekruse S, Anderson WF, Rosenberg PS, Gillison ML. Human papillomavirus (HPV) and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011 Nov 10;29(32):4294-30.

Jordan RC, Lingen MW, Perez-Ordonez B, He X, Pickard R, Koluder M, Jiang B, Wakely P, Xiao W, Gillison ML. Validation of Methods for Oropharyngeal Cancer HPV Status Determination in US Cooperative Group Trials. Am J Surg Pathol. 2012 Jul;36(7):945-954.

Gillison ML, Zhang Q, Jordan RC, Xiao W, Westra WH, Trotti A, Spencer S, Harris J, Chung CH, Ang KK. Tobacco Smoking and Increased Risk of Death and Progression for Patients With p16-Positive and p16-Negative Oropharyngeal Cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2012 Jun 10;30(17):2102-11.

Kong CS, Cao H, Kwok S, Nguyen CM, Jordan RC, Beaudry VG, Attardi LD, Le QT. Loss of the p53/p63 target PERP is an early event in oral carcinogenesis and correlates with higher rate of local relapse. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013 Jan; 115(1):95-103. PMID: 23217540.

Chung CH, Lee JW, Slebos RJ, Howard JD, Perez J, Kang H, Fertig EJ, Considine M, Gilbert J, Murphy BA, Nallur S, Paranjape T, Jordan RC, Garcia J, Burtness B, Forastiere AA, Weidhaas JB. 3'-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol. 2014 Nov;25(11):2230-6. PMID: 25081901.

Lingen MW, Xiao W, Schmitt A, Jiang B, Pickard R, Kreinbrink P, Perez-Ordonez B, Jordan RC, Gillison ML. Low etiologic fraction for high-risk human papillomavirus in oral cavity squamous cell carcinomas. Oral Oncol. 2013 Jan; 49(1):1-8. PMID: 22841678.

Ang KK, Zhang Q, Rosenthal DI, Nguyen-Tan PF, Sherman EJ, Weber RS, Galvin JM, Bonner JA, Harris J, El-Naggar AK, Gillison ML, Jordan RC, Konski AA, Thorstad WL, Trotti A, Beitler JJ, Garden AS, Spanos WJ, Yom SS, Axelrod RS. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol. 2014 Sep 20; 32(27):2940-50. PMID: 25154822.

Chung CH, Zhang Q, Kong CS, Harris J, Fertig EJ, Harari PM, Wang D, Redmond KP, Shenouda G, Trotti A, Raben D, Gillison ML, Jordan RC, Le QT. p16 Protein Expression and Human Papillomavirus Status As Prognostic Biomarkers of Nonoropharyngeal Head and Neck Squamous Cell Carcinoma. J Clin Oncol. 2014 Dec 10; 32(35):3930-8. PMID: 25267748.

Harari PM, Harris J, Kies MS, Myers JN, Jordan RC, Gillison ML, Foote RL, Machtay M, Rotman M, Khuntia D, Straube W, Zhang Q, Ang K. Postoperative chemoradiotherapy and cetuximab for high-risk squamous cell carcinoma of the head and neck: Radiation Therapy Oncology Group RTOG-0234.  J Clin Oncol. 2014 Aug 10;32(23):2486-95. PMID: 25002723.

Nguyen-Tan PF, Zhang Q, Ang KK, Weber RS, Rosenthal DI, Soulieres D, Kim H, Silverman C, Raben A, Galloway TJ, Fortin A, Gore E, Westra WH, Chung CH, Jordan RC, Gillison ML, List M, Le QT. Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity. J Clin Oncol. 2014 Dec 1;32(34):3858-66. PMID: 25366680.

Chou A, Schulman JM, Gross AJ, Jordan RC, Ramos DM. Gingival pustules and sterile diffuse sclerosing osteomyelitis as a feature of synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016 May;121(5):e116-22.  PMID: 26619759.

Meet our other physicians